Bal Pharma Fixes September 17 as Record Date for ₹1.20 Final Dividend
Bal Pharma Limited has set September 17, 2026, as the record date for its final dividend. Shareholders will receive ₹1.20 per equity share (12% of face value). The dividend payment is scheduled for on or after September 24, 2026. Information on TDS and submission of relevant forms is also provided.
The dividend payment is a positive financial event for shareholders, but the amount is a standard declaration and does not represent a significant change in the company's financial trajectory or valuation.
The announcement concerns the payment of a final dividend, which is generally viewed positively by shareholders as it represents a return on their investment.
Bal Pharma Limited has announced that the record date for the payment of its final dividend for the financial year 2025-26 has been fixed as Thursday, September 17, 2026. The dividend rate is ₹1.20 per equity share of ₹10 face value, which amounts to 12% of the face value.
The dividend will be paid on or after September 24, 2026, to the equity shareholders who are on the company's register of members or beneficial owners in the depositories' records as of the record date.
The company has also provided detailed information regarding tax deduction at source (TDS) on dividend income. Generally, no tax will be deducted for resident individual shareholders with valid PAN details if the total dividend amount does not exceed ₹10,000. Shareholders eligible for Nil or lower TDS rates are advised to submit the requisite forms and supporting documents through the Registrar and Transfer Agent, MUFG Intime India Private Limited, or via email. Shareholders are also urged to ensure their bank account details are updated for timely dividend credit.
What to do with a filing like this
Bal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bal Pharma Limited. Read the original for the full detail.